Recent Investment Analysts’ Ratings Changes for Vertex Pharmaceuticals (VRTX)

Several brokerages have updated their recommendations and price targets on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) in the last few weeks:

• 5/18/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 5/10/2026 – Vertex Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/6/2026 – Vertex Pharmaceuticals had its price target raised by Barclays PLC from $607.00 to $615.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $612.00 to $616.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $541.00 to $543.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target lowered by Sanford C. Bernstein from $577.00 to $572.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $437.00 to $436.00. They now have a “hold” rating on the stock.
• 5/2/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/30/2026 – Vertex Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $441.00 to $437.00. They now have a “hold” rating on the stock.
• 4/27/2026 – Vertex Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/14/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/10/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $596.00 to $612.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. The trade was a 5.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amit Sachdev sold 1,846 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $897,802.10. Following the completion of the transaction, the executive vice president directly owned 55,570 shares of the company’s stock, valued at approximately $27,026,469.50. This trade represents a 3.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 21,189 shares of company stock worth $9,923,036. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.